Patents by Inventor Michael Monrad Grandal

Michael Monrad Grandal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies targeting PD-1, TIM-3, and LAG-3
    Patent number: 11939380
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 26, 2024
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20240052032
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, such as cancer.
    Type: Application
    Filed: October 19, 2023
    Publication date: February 15, 2024
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Anti-lag-3 antibodies and compositions
    Patent number: 11834503
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: December 5, 2023
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • ANTI-CD73 ANTIBODIES AND COMPOSITIONS
    Publication number: 20230227573
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 20, 2023
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Michael Monrad GRANDAL, Torben GJETTING, Johan LANTTO, Janus Schou JAKOBSEN, Randi Westh HANSEN, Camilla FRÖHLICH
  • Anti-CD73 antibodies and compositions
    Patent number: 11634500
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 25, 2023
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Michael Monrad Grandal, Torben Gjetting, Johan Lantto, Janus Schou Jakobsen, Randi Westh Hansen, Camilla Fröhlich
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20230105714
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: May 11, 2022
    Publication date: April 6, 2023
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • ANTI-NKG2A ANTIBODIES AND COMPOSITIONS
    Publication number: 20220389100
    Abstract: This invention relates to anti-NKG2A antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.
    Type: Application
    Filed: May 31, 2022
    Publication date: December 8, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Randi Westh Hansen, Franziska Katharina Uhlenbrock, Nikolaj Dietrich, Anne Worsaae, Michael Monrad Grandal
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20220380470
    Abstract: This invention relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the invention are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: June 7, 2022
    Publication date: December 1, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20220363757
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Application
    Filed: June 7, 2022
    Publication date: November 17, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Anti-LAG-3 antibodies and compositions
    Patent number: 11390676
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • Anti-TIM-3 antibodies and compositions
    Patent number: 11390674
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Trine Lindsted, Torben Gjetting, Gunther Roland Galler, Monika Gad, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20220056126
    Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 24, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Vikram Kjøller BHATIA, Torben GJETTING, Camilla FRÖHLICH, Gunther Roland GALLER, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • ANTI-CD73 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210070876
    Abstract: This invention relates to anti-CD73 antibodies and methods of using them in treating diseases and conditions related to CD73 activity, e.g., cancer.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Michael Monrad GRANDAL, Torben GJETTING, Johan LANTTO, Janus Schou JAKOBSEN, Randi Westh HANSEN, Camilla FRÖHLICH
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20200407444
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: April 5, 2018
    Publication date: December 31, 2020
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • Anti-MET antibodies and compositions
    Patent number: 10450376
    Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 22, 2019
    Assignee: Symphogen A/S
    Inventors: Thomas Bouquin, Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Thomas Tuxen Poulsen, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Karsten Wessel Eriksen, Paolo Conrotto
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20190276531
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: April 11, 2017
    Publication date: September 12, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • ANTI-MET ANTIBODIES AND COMPOSITIONS
    Publication number: 20180327500
    Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
    Type: Application
    Filed: September 15, 2015
    Publication date: November 15, 2018
    Inventors: Thomas Bouquin, Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Thomas Tuxen Poulsen, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Karsten Wessel Eriksen, Paolo Conrotto